CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 40 enrolled
Drug / intervention
Secukinumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03149900
NCT03149900N/ACompleted
CompareCT.gov

Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients

Diamant Thaci·observational·Posted May 11, 2017·Updated Aug 16, 2019

In Brief

An observational study evaluating Secukinumab for Psoriasis Vulgaris. Completed, enrolled 40 participants across 1 site.

Detailed Summary

To identify possible genetic associations of clinical response to anti-IL-17A (Secukinumab) treatment in psoriasis using a combined gene association study and gene expression analysis. To investigate the influence of IL-17A on the cutaneous microbial flora and to analyse cutaneous antimicrobial peptide expression in the skin of patients with psoriasis prior to, and during, treatment with Secukinumab to determine the extent to which the microbial flora is associated with response to treatment, as determined by the PASI75, PASI90, PGA- and DLQI improvement.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesGermany
CollaboratorsNovartis

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMay 11, 2017
Enrollment StartOct 1, 2016
Primary CompletionJul 25, 2019
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 9.1 years ago

Interventions

Secukinumabdrug

See Arm Description